Research ExplorerPublicationsDirected evolution of a recombinase that excises the proviru...

Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity

Standard

Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity. / Karpinski, Janet; Hauber, Ilona; Chemnitz, Jan; Schäfer, Carola; Paszkowski-Rogacz, Maciej; Chakraborty, Deboyoti; Beschorner, Niklas; Hofmann-Sieber, Helga; Lange, Ulrike C; Grundhoff, Adam; Hackmann, Karl; Schrock, Evelin; Abi-Ghanem, Josephine; Pisabarro, M Teresa; Surendranath, Vineeth; Schambach, Axel; Lindner, Christoph; van Lunzen, Jan; Hauber, Joachim; Buchholz, Frank.

In: NAT BIOTECHNOL, Vol. 34, No. 4, 04.2016, p. 401-9.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Karpinski, J, Hauber, I, Chemnitz, J, Schäfer, C, Paszkowski-Rogacz, M, Chakraborty, D, Beschorner, N, Hofmann-Sieber, H, Lange, UC, Grundhoff, A, Hackmann, K, Schrock, E, Abi-Ghanem, J, Pisabarro, MT, Surendranath, V, Schambach, A, Lindner, C, van Lunzen, J, Hauber, J & Buchholz, F 2016, 'Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity', NAT BIOTECHNOL, vol. 34, no. 4, pp. 401-9. https://doi.org/10.1038/nbt.3467

APA

Karpinski, J., Hauber, I., Chemnitz, J., Schäfer, C., Paszkowski-Rogacz, M., Chakraborty, D., Beschorner, N., Hofmann-Sieber, H., Lange, U. C., Grundhoff, A., Hackmann, K., Schrock, E., Abi-Ghanem, J., Pisabarro, M. T., Surendranath, V., Schambach, A., Lindner, C., van Lunzen, J., Hauber, J., & Buchholz, F. (2016). Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity. NAT BIOTECHNOL, 34(4), 401-9. https://doi.org/10.1038/nbt.3467

Vancouver

Karpinski J, Hauber I, Chemnitz J, Schäfer C, Paszkowski-Rogacz M, Chakraborty D et al. Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity. NAT BIOTECHNOL. 2016 Apr;34(4):401-9. https://doi.org/10.1038/nbt.3467

Bibtex

@article{761c68dce72743c49bb216137da163af,
title = "Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity",
abstract = "Current combination antiretroviral therapies (cART) efficiently suppress HIV-1 reproduction in humans, but the virus persists as integrated proviral reservoirs in small numbers of cells. To generate an antiviral agent capable of eradicating the provirus from infected cells, we employed 145 cycles of substrate-linked directed evolution to evolve a recombinase (Brec1) that site-specifically recognizes a 34-bp sequence present in the long terminal repeats (LTRs) of the majority of the clinically relevant HIV-1 strains and subtypes. Brec1 efficiently, precisely and safely removes the integrated provirus from infected cells and is efficacious on clinical HIV-1 isolates in vitro and in vivo, including in mice humanized with patient-derived cells. Our data suggest that Brec1 has potential for clinical application as a curative HIV-1 therapy.",
author = "Janet Karpinski and Ilona Hauber and Jan Chemnitz and Carola Sch{\"a}fer and Maciej Paszkowski-Rogacz and Deboyoti Chakraborty and Niklas Beschorner and Helga Hofmann-Sieber and Lange, {Ulrike C} and Adam Grundhoff and Karl Hackmann and Evelin Schrock and Josephine Abi-Ghanem and Pisabarro, {M Teresa} and Vineeth Surendranath and Axel Schambach and Christoph Lindner and {van Lunzen}, Jan and Joachim Hauber and Frank Buchholz",
year = "2016",
month = apr,
doi = "10.1038/nbt.3467",
language = "English",
volume = "34",
pages = "401--9",
journal = "NAT BIOTECHNOL",
issn = "1087-0156",
publisher = "NATURE PUBLISHING GROUP",
number = "4",

}

RIS

TY - JOUR

T1 - Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity

AU - Karpinski, Janet

AU - Hauber, Ilona

AU - Chemnitz, Jan

AU - Schäfer, Carola

AU - Paszkowski-Rogacz, Maciej

AU - Chakraborty, Deboyoti

AU - Beschorner, Niklas

AU - Hofmann-Sieber, Helga

AU - Lange, Ulrike C

AU - Grundhoff, Adam

AU - Hackmann, Karl

AU - Schrock, Evelin

AU - Abi-Ghanem, Josephine

AU - Pisabarro, M Teresa

AU - Surendranath, Vineeth

AU - Schambach, Axel

AU - Lindner, Christoph

AU - van Lunzen, Jan

AU - Hauber, Joachim

AU - Buchholz, Frank

PY - 2016/4

Y1 - 2016/4

N2 - Current combination antiretroviral therapies (cART) efficiently suppress HIV-1 reproduction in humans, but the virus persists as integrated proviral reservoirs in small numbers of cells. To generate an antiviral agent capable of eradicating the provirus from infected cells, we employed 145 cycles of substrate-linked directed evolution to evolve a recombinase (Brec1) that site-specifically recognizes a 34-bp sequence present in the long terminal repeats (LTRs) of the majority of the clinically relevant HIV-1 strains and subtypes. Brec1 efficiently, precisely and safely removes the integrated provirus from infected cells and is efficacious on clinical HIV-1 isolates in vitro and in vivo, including in mice humanized with patient-derived cells. Our data suggest that Brec1 has potential for clinical application as a curative HIV-1 therapy.

AB - Current combination antiretroviral therapies (cART) efficiently suppress HIV-1 reproduction in humans, but the virus persists as integrated proviral reservoirs in small numbers of cells. To generate an antiviral agent capable of eradicating the provirus from infected cells, we employed 145 cycles of substrate-linked directed evolution to evolve a recombinase (Brec1) that site-specifically recognizes a 34-bp sequence present in the long terminal repeats (LTRs) of the majority of the clinically relevant HIV-1 strains and subtypes. Brec1 efficiently, precisely and safely removes the integrated provirus from infected cells and is efficacious on clinical HIV-1 isolates in vitro and in vivo, including in mice humanized with patient-derived cells. Our data suggest that Brec1 has potential for clinical application as a curative HIV-1 therapy.

U2 - 10.1038/nbt.3467

DO - 10.1038/nbt.3467

M3 - SCORING: Journal article

C2 - 26900663

VL - 34

SP - 401

EP - 409

JO - NAT BIOTECHNOL

JF - NAT BIOTECHNOL

SN - 1087-0156

IS - 4

ER -